Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

102.84 +0.27 (+0.26%)
Official Closing Price Updated: 7:00 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 984,688
Open 102.70
Bid (Size) 101.79 (1)
Ask (Size) 103.25 (2)
Prev. Close 102.57
Today's Range 102.28 - 103.00
52wk Range 92.19 - 108.78
Shares Outstanding N/A
Dividend Yield 3.37%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+1.82%
+1.82%
1 Month
+8.12%
+8.12%
3 Month
+0.12%
+0.12%
6 Month
+7.97%
+7.97%
1 Year
+1.43%
+1.43%

More News

Read More
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
3 Magnificent Stocks That Are Passive Income Machines
Via The Motley Fool
Is NYSE:NVS a Good Fit for Dividend Investing?
Via Chartmill
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
The 3 Best Mutual Funds to Buy in May 2024
Via InvestorPlace
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Via Benzinga
3 Biotech Stocks to Sell in May Before They Crash & Burn
Via InvestorPlace
Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Axmed raises $2 million to transform access to critical medicines in low and middle income countries
Via News Direct
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
2 Magnificent Dividend Stocks to Hold for the Next Decade
Via The Motley Fool
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
Via Benzinga
Exposures Product Safety
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
Via Investor's Business Daily
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
Via Talk Markets
What's Going On With Pfizer Stock On Thursday?
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
Why Novartis Stock Topped the Market on Tuesday
Via The Motley Fool
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Via Benzinga
Exposures Product Safety
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.